Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
665.8 INR | -0.49% | -3.40% | -5.09% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 55.94 and 48.47 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.09% | 3.19B | C+ | ||
+22.56% | 46.4B | B- | ||
-1.51% | 41.75B | B | ||
+48.83% | 41.37B | A | ||
-3.42% | 29.71B | C | ||
+10.13% | 26.01B | B- | ||
-20.44% | 19.52B | B | ||
+26.45% | 12.43B | C+ | ||
-0.14% | 12.18B | B+ | ||
-0.47% | 12.13B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SYNGENE Stock
- Ratings Syngene International Limited